Company · founded 2003
Acceleron Pharma (United States)
Cambridge, United States · acceleronpharma.com
- Citations, last 5 years
- 590
- Works, last 5 years
- 39
- h-index
- 151
- Scientists listed
- 2
- Grants since 2016
- 5
Grants received
2023–2025 · research · R41
Identification of Mixed NOP/mu partial agonists as lead compounds for treatment of methamphetamine use disorder
Andrea Cippitelli · Acceleron Pharma (United States) · funded by National Institutes of Health
2022–2025 · cooperative agreement · U01
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder
Frances Rudnick Levin · Acceleron Pharma (United States) · funded by National Institutes of Health
2022–2025 · cooperative agreement · U01
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder
Frances Rudnick Levin · Acceleron Pharma (United States) · funded by National Institutes of Health
2022–2025 · cooperative agreement · U01
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder
Frances Rudnick Levin · Acceleron Pharma (United States) · funded by National Institutes of Health
2018–2021 · research · R41
The Kappa Partial Agonist PPL-103 as a Potential Cocaine Abuse Pharmacotherapy
Lawrence R Toll · Acceleron Pharma (United States) · funded by National Institutes of Health